Literature DB >> 3392373

Immune responses to Aspergillus in cystic fibrosis.

R Zeaske1, W T Bruns, J N Fink, P A Greenberger, H Colby, J L Liotta, M Roberts.   

Abstract

Aspergillus fumigatus (Af) is well recognized in its ability to colonize the respiratory tract in cystic fibrosis (CF). Furthermore, a number of the immune responses of the patient with CF to this organism have been characterized, and the immune inflammatory response to Af may result in allergic bronchopulmonary aspergillosis (ABPA). This study evaluated a series of immunologic parameters in 75 patients with CF in order to characterize more fully the spectrum of immune responses of those patients to Af and to clarify the relationship of those responses to the clinical features of ABPA. The patients could be classified into four groups, depending on the clinical and immunologic findings. Eight (10.7%) of the 75 patients had clinical and laboratory evidence of ABPA, including immediate cutaneous reactivity to Af, eosinophilia, elevated total serum IgE, elevated serum IgE-Af or IgG-Af, and precipitating antibody to Af. Ten (13.3%) patients had these features, except that the total serum IgE level was within the normal range. Forty (53.5%) of the patients had no significant criteria for ABPA but had varying immunologic responses to Af, such as immediate cutaneous reactivity to Af in 25 patients and elevated serum IgE-Af and/or IgG-Af in 19 patients. Seventeen (22.7%) patients had no evidence of an immunologic response, as determined by skin testing and serologic assays. The study demonstrated that the response of patients with CF to Af ranges from clinically apparent ABPA to a possible variant of ABPA, to a nondiagnostic group of features consistent with sensitization to Af or to no characteristic immune response.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3392373     DOI: 10.1016/0091-6749(88)90054-1

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  14 in total

Review 1.  Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.

Authors:  A P Knutsen; R G Slavin
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 2.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

3.  Risk factors for allergic bronchopulmonary aspergillosis and sensitisation to Aspergillus fumigatus in patients with cystic fibrosis.

Authors:  Nicole Ritz; Roland A Ammann; Carmen Casaulta Aebischer; Franziska Schoeni-Affolter; Martin H Schoeni
Journal:  Eur J Pediatr       Date:  2005-05-31       Impact factor: 3.183

Review 4.  Allergic and invasive aspergillosis.

Authors:  J P Burnie
Journal:  J R Soc Med       Date:  1995       Impact factor: 5.344

Review 5.  Aspergillus fumigatus and aspergillosis.

Authors:  J P Latgé
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

Review 6.  How Environmental Fungi Cause a Range of Clinical Outcomes in Susceptible Hosts.

Authors:  Steven T Denham; Morgan A Wambaugh; Jessica C S Brown
Journal:  J Mol Biol       Date:  2019-05-09       Impact factor: 5.469

7.  Longitudinal study of Aspergillus fumigatus strains isolated from cystic fibrosis patients.

Authors:  C Neuvéglise; J Sarfati; J P Debeaupuis; H Vu Thien; J Just; G Tournier; J P Latgé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-10       Impact factor: 3.267

Review 8.  Allergic bronchopulmonary aspergillosis.

Authors:  Richard B Moss
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

9.  Cystic fibrosis and allergic bronchopulmonary aspergillosis.

Authors:  E J Simmonds; J M Littlewood; E G Evans
Journal:  Arch Dis Child       Date:  1990-05       Impact factor: 3.791

Review 10.  Fungus-Specific CD4 T Cells as Specific Sensors for Identification of Pulmonary Fungal Infections.

Authors:  Alexander Scheffold; Carsten Schwarz; Petra Bacher
Journal:  Mycopathologia       Date:  2017-11-22       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.